Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kenya Mother-Daughter Cervical Cancer Eradication Program
NCT06411938Active, not recruiting
- Sponsor
- Indiana University
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC) and human papillomavirus infection (2 arms), sponsored by Indiana University. Primary endpoints: Association between biopsy-proven (CIN2/3+) VIA abnormality and HR-HPV DNA testing and Acceptability of the Mother Daughter Program. Started Apr 2024; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)human papillomavirus infection
Beyond the preview
Go deeper on NCT06411938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411938.